Structure Therapeutics (NASDAQ:GPCR) Hits New 12-Month Low – Time to Sell?

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) shares hit a new 52-week low during mid-day trading on Thursday. The stock traded as low as $25.49 and last traded at $25.61, with a volume of 205518 shares changing hands. The stock had previously closed at $26.68.

Analyst Ratings Changes

A number of research firms recently weighed in on GPCR. Citigroup restated a “market outperform” rating on shares of Structure Therapeutics in a research note on Friday, August 7th. Canaccord Genuity Group set a $111.00 price target on shares of Structure Therapeutics in a research note on Friday, August 7th. Citizens Jmp reiterated a “market outperform” rating and set a $110.00 price target on shares of Structure Therapeutics in a report on Wednesday, September 9th. Wall Street Zen downgraded shares of Structure Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, October 3rd. Finally, HC Wainwright restated a “buy” rating on shares of Structure Therapeutics in a report on Wednesday, September 9th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Structure Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $110.91.

Structure Therapeutics Stock Performance

The firm has a 50-day moving average price of $43.43 and a two-hundred day moving average price of $45.17. The firm has a market cap of $1.75 billion, a price-to-earnings ratio of -25.20 and a beta of -1.30.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). Research analysts anticipate that Structure Therapeutics Inc. Sponsored ADR will post -1.87 earnings per share for the current year.

Institutional Investors Weigh In On Structure Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Assetmark Inc. boosted its stake in shares of Structure Therapeutics by 21.4% during the first quarter. Assetmark Inc. now owns 2,544 shares of the company’s stock valued at $123,000 after acquiring an additional 449 shares during the last quarter. TrueMark Investments LLC lifted its position in Structure Therapeutics by 1.4% during the first quarter. TrueMark Investments LLC now owns 34,377 shares of the company’s stock worth $1,657,000 after buying an additional 484 shares during the period. Sterling Capital Management LLC acquired a new stake in Structure Therapeutics in the 1st quarter worth about $28,000. IFP Advisors Inc acquired a new stake in shares of Structure Therapeutics in the second quarter worth approximately $46,000. Finally, Cetera Investment Advisers grew its holdings in Structure Therapeutics by 17.0% in the first quarter. Cetera Investment Advisers now owns 7,720 shares of the company’s stock valued at $372,000 after purchasing an additional 1,124 shares during the period. 91.78% of the stock is currently owned by institutional investors and hedge funds.

About Structure Therapeutics

Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing oral small-molecule medicines for chronic metabolic and cardiopulmonary diseases. The company uses structure-based drug discovery and related technologies to identify therapies intended to address conditions with significant unmet medical needs.

Its lead product candidate is GSBR-1290, an investigational oral small-molecule agonist of the glucagon-like peptide-1 (GLP-1) receptor being developed for obesity and type 2 diabetes.